AIKI Insider Trading Activity and SEC Form 4 Filings
AIKI insider trading summary
No open-market insider purchases or sales of AIkido Pharma Inc. (AIKI) have been reported on SEC Form 4 in the past 12 months.
Latest AIKI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 19, 2022 | Soo Yu | Director | Buy | $18K (5,000 @ $3.59) |
| Dec 19, 2022 | Kyle Michael Wool | Director | Buy | $18K (5,000 @ $3.59) |
| Dec 16, 2022 | Soo Yu | Director | Buy | $19K (5,000 @ $3.71) |
| Dec 16, 2022 | Kyle Michael Wool | Director | Buy | $19K (5,000 @ $3.71) |
| Dec 15, 2022 | Soo Yu | Director | Buy | $18K (5,000 @ $3.69) |
| Dec 15, 2022 | Kyle Michael Wool | Director | Buy | $18K (5,000 @ $3.69) |
| Dec 14, 2022 | Kyle Michael Wool | Director | Buy | $17K (4,500 @ $3.69) |
| Dec 14, 2022 | Soo Yu | Director | Buy | $17K (4,500 @ $3.69) |
| Dec 14, 2022 | Anthony Hayes | CEO | Buy | $17K (4,500 @ $3.69) |
| Dec 13, 2022 | Kyle Michael Wool | Director | Buy | $18K (5,000 @ $3.70) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.